[212Pb]VMT-alpha-NET

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

EsthesioneuroblastomaGastrointestinal Neuroendocrine TumorsHead and Neck TumorsKidney CancersNasopharyngeal CarcinomaOlfactory NeuroblastomaParagangliomasPheochromocytoma

Phase 1

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

RecruitingNCT06427798

National Cancer Institute (NCI)Gastrointestinal Neuroendocrine Tumors, Paragangliomas, Pheochromocytoma +1

Start: 2025-02-07End: 2039-07-01Target: 66Updated: 2026-07-06

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

RecruitingNCT06479811

National Cancer Institute (NCI)Esthesioneuroblastoma, Gastrointestinal Neuroendocrine Tumors, Head and Neck Tumors +7

Start: 2025-08-19End: 2032-01-01Target: 120Updated: 2026-06-12